Taken together, these data demonstrate for the first time that NLRP3 inhibition, after disease onset and using a brain penetrant compound (VEN-02XX) leads to robust symptomatic efficacy with specific improvements in learning and memory in the context of AD pathology. This evidence concerns the gene NLRP3 and Alzheimer disease.